TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of “Hold” from Brokerages

TScan Therapeutics, Inc. (NASDAQ:TCRX) has received a consensus recommendation of “Hold” from the seven research firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $6.60.

A number of analysts have weighed in on the stock. HC Wainwright decreased their target price on shares of TScan Therapeutics from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Thursday, November 13th. Weiss Ratings restated a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Thursday. BTIG Research lowered shares of TScan Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, November 4th. Morgan Stanley cut shares of TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a research report on Friday, November 14th. Finally, Needham & Company LLC dropped their target price on shares of TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, November 4th.

TScan Therapeutics Stock Down 3.4%

Shares of TCRX opened at $1.14 on Friday. The stock’s 50-day moving average price is $1.05 and its two-hundred day moving average price is $1.55. TScan Therapeutics has a 12 month low of $0.88 and a 12 month high of $2.67. The company has a market capitalization of $64.70 million, a PE ratio of -1.02 and a beta of 1.04. The company has a current ratio of 6.44, a quick ratio of 6.44 and a debt-to-equity ratio of 0.23.

TScan Therapeutics (NASDAQ:TCRX) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.07. TScan Therapeutics had a negative return on equity of 73.33% and a negative net margin of 1,692.96%.The company had revenue of $2.51 million during the quarter, compared to analysts’ expectations of $1.98 million. On average, analysts anticipate that TScan Therapeutics will post -1.12 EPS for the current year.

Insider Buying and Selling at TScan Therapeutics

In other TScan Therapeutics news, major shareholder Lynx1 Capital Management Lp acquired 80,069 shares of the stock in a transaction dated Friday, December 19th. The stock was purchased at an average cost of $0.90 per share, with a total value of $72,062.10. Following the transaction, the insider owned 7,937,416 shares in the company, valued at approximately $7,143,674.40. The trade was a 1.02% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Over the last three months, insiders bought 161,801 shares of company stock valued at $145,621. Company insiders own 4.35% of the company’s stock.

Institutional Investors Weigh In On TScan Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. increased its holdings in TScan Therapeutics by 6.0% in the first quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock worth $235,000 after purchasing an additional 9,676 shares in the last quarter. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of TScan Therapeutics during the 2nd quarter worth approximately $29,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of TScan Therapeutics during the 2nd quarter worth approximately $111,000. Letko Brosseau & Associates Inc. increased its stake in shares of TScan Therapeutics by 24.4% in the 2nd quarter. Letko Brosseau & Associates Inc. now owns 95,875 shares of the company’s stock valued at $139,000 after acquiring an additional 18,775 shares in the last quarter. Finally, Catalyst Funds Management Pty Ltd acquired a new position in shares of TScan Therapeutics during the 2nd quarter valued at $26,000. Institutional investors and hedge funds own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.